BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 2, 2023
Home » Stock Winners and Losers For The Week
X
/images/Cortellis_Flagship_Logo_TM_RGB_Color.png

Upgrade your daily dose of biopharma and medtech news

Subscribe to BioWorld™ news services

See subscription options

Stock Winners and Losers For The Week

Dec. 6, 2004
No Comments

Article reprints
BioWorld MedTech

    Popular Stories

    • Today's news in brief

      BioWorld MedTech
      BioWorld MedTech briefs for December 1, 2023.
    • Joint pain

      Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

      BioWorld Science
      Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.
    • Stock chart with falling red arrow

      ‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

      BioWorld
      For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...
    • COVID-19 mRNA vaccine vials, syringe

      Japan approves first self-amplifying mRNA COVID-19 vaccine from CSL, Arcturus

      BioWorld
      In a global first, Japan's Ministry of Health, Labor and Welfare has approved CSL Ltd.’s and Arcturus Therapeutics Inc.’s self-amplifying messenger RNA (sa-mRNA)...
    • heart-cardio-data.png

      Avidity, BMS sign $2.3B cardiovascular deal for new RNA class

      BioWorld
      In a deal that could bring Avidity Biosciences Inc. $2.3 billion if all milestones are met, Bristol Myers Squibb Co. gained global rights to Avidity’s antibody...
    black cortellis ad

    BioWorld Premium

    Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

    Subscribe
    • BioWorld
      • Today's news
      • Analysis and data insight
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Newco news
      • Opinion
      • Regulatory
      • Science
    • BioWorld MedTech
      • Today's news
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Newco news
      • Opinion
      • Regulatory
      • Science
    • BioWorld Asia
      • Today's news
      • Analysis and data insight
      • Australia
      • China
      • Clinical
      • Deals and M&A
      • Financings
      • Newco news
      • Regulatory
      • Science
    • BioWorld Science
      • Today's news
      • Biomarkers
      • Cancer
      • Conferences
      • Endocrine/Metabolic
      • Immune
      • Infection
      • Neurology/Psychiatric
      • Patents
    • More
      • About
      • Advertise with BioWorld
      • Archives
      • Article reprints and permissions
      • Contact us
      • Cookie policy
      • Copyright notice
      • Data methodology
      • Podcasts
      • Privacy policy
      • Share your news with BioWorld
      • Staff
      • Terms of use
      • Topic alerts
    Follow Us

    Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing